

REMARKS


The paragraph that was introduced in the Preliminary Amendment dated November 15, 2001, is hereby further amended to introduce additional identification of a parent application by patent number, to correct a typographical error in the serial number of the same parent case, and to change the descriptive reference to the same parent case from "division" to "continuation".

Claim 1 has been amended to delete the preposition "or" that was inadvertently introduced in the Preliminary Amendment dated November 15, 2001. Support for the deletion introduced in the present Supplemental Amendment is found in claim 1 as initially filed. *See, e.g.*, Application, p. 31, *l.* 19.

No new claims are introduced by the present amendment and no pending claims are cancelled. The number of pending claims remains the same as of the filing of the previous Amendment "RCE", and as indicated in the Notice of Allowance dated November 8, 2002.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Respectfully submitted,



Jesús Juanós i Timoneda, PhD
Attorney for Applicants
Reg. No. 43,332

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-3742
Dated: March 25, 2003


Version with Markings to Show Changes Made

Amend the paragraph that was introduced on p. 4, between the Title of the Invention and line 4, in the Preliminary Amendment dated November 15, 2001, as follows:

This application is a [divisional] continuation of prior application U.S. Serial No. 0[9]8/938,602, filed September 26, 1997, now U.S. Pat. No. 6,380,194, which claims priority from United States provisional application Serial No. 60/027,260, filed October 1, 1996, the contents of which are hereby incorporated by reference.

Amend Claim 1 as follows:

1. (Five times amended) A compound of formula



a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof, wherein

- R^1 and R^2 are each independently selected from hydrogen; hydroxy; amino; C_{1-6} alkyl; C_{1-6} alkyloxy; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; Ar^1 ; mono- or di(C_{1-6} alkyl)amino; mono- or di(C_{1-6} alkyl)aminocarbonyl; dihydro-2(3*H*)-furanone; C_{1-6} alkyl substituted with one or two substituents each independently selected from amino, imino, aminocarbonyl, aminocarbonylamino, hydroxy, hydroxy C_{1-6} alkyloxy, carboxyl, mono- or di(C_{1-6} alkyl)amino, C_{1-6} alkyloxycarbonyl and thienyl; or
- R^1 and R^2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C_{1-6} alkyl)amino C_{1-4} alkylidene;
- R^3 is hydrogen, Ar^1 , C_{1-6} alkylcarbonyl, C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl, C_{1-6} alkyl substituted with C_{1-6} alkyloxycarbonyl; and
- R^4 , R^5 , R^7 and R^8 are each independently selected from hydrogen, hydroxy, halo, C_{1-6} alkyl, C_{1-6} alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy;

R⁶ is aminocarbonyl; [or]

L is C₁₋₁₀alkyl; C₃₋₁₀alkenyl; C₃₋₁₀alkynyl; C₃₋₇cycloalkyl; or

L is C₁₋₁₀alkyl substituted with one or two substituents independently selected from the group consisting of C₃₋₇cycloalkyl; indolyl or indolyl substituted with one, two, three or four substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, or C₁₋₆alkylcarbonyl; and phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, or C₁₋₆alkylcarbonyl; and, Ar¹ is phenyl, or phenyl substituted with one, two or three substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, nitro or trifluoromethyl.